Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
30 August 2022 | Story André Damons | Photo André Damons
UFS Nuclear Medicine
The team of doctors in the Department of Nuclear Medicine behind the success story are, from the left (standing): Dr Osayande Evbuomwan, nuclear medicine specialist and Senior Lecturer; Dr Gerrit Engelbrecht, Clinical Head of the Department of Nuclear Medicine at the UFS; and Dr Walter Endres, nuclear medicine registrar. In front is Dr Tebatso Tebeila, nuclear medicine registrar.

The University of the Free State (UFS) Department of Nuclear Medicine is proud to announce the successful treatment outcome of a patient with metastatic castrate-resistant prostate cancer (MCRPC) – an advanced stage of prostate cancer – by using Lutetium 177 PSMA (Lu-177 PSMA) therapy. This was initially a case of advanced stage prostate cancer, which had failed first-line chemotherapy, leaving little or no other treatment options.

This is a proud and happy moment for the department and the UFS, which started this treatment just over a year ago. The university and the Free State province are now joining other South African medical universities, such as the University of Pretoria, and other provinces in using this method to treat MCRPC patients. Lutetium 177 PSMA (Lu-177 PSMA) therapy is used on MCRPC patients who are not eligible for chemotherapy or have failed first- or second-line chemotherapy.

Dr Gerrit Engelbrecht, Clinical Head of the Department of Nuclear Medicine at the UFS, says the department is proud to be able to offer this treatment option to some of these patients. “It is a big win for the Free State and our oncology patients to be able to offer these expert services.” The UFS and Universitas Academic Hospital have now been able to join up with other academic institutions and hospitals in other provinces to offer these services. So far, three patients have been offered this therapeutic option, with the third patient currently undergoing his treatment.

Funds and equipment for proper treatment selection are needed

The expertise is no longer an issue for the UFS, as Dr Osayande Evbuomwan, nuclear medicine specialist and consultant, was trained and exposed to this therapy at the University of the Witwatersrand during his training as a nuclear medicine resident. Current registrars in the Department of Nuclear Medicine at the UFS are also being trained in the application of this treatment modality. However, proper patient selection is key in the management of these cases with Lu 177 PSMA. Without a PET/CT camera, it is challenging to appropriately select the patients who are most likely to respond to this therapy. This is an example of how PET/CT is crucial in the management and monitoring of oncology patients.

Both Drs Engelbrecht and Evbuomwan hope that the training of more registrars will increase their department’s capacity to treat more patients. They also hope that funds will be made available to acquire a much-needed PET/CT camera, which will greatly assist them in identifying the correct patients in need of this treatment. 

With the permission of the patient, the images above show the dramatic treatment response following Lu-177 PSMA therapy. The images on the left show widespread bone disease from the prostate cancer, including the skull. The images on the right show the dramatic response after completing four cycles of Lu 177 PSMA, with the normal excretion of the radiotracer seen in the liver, kidneys, and bladder.


Treatment puts the department, UFS, and hospital on the map

According to Dr Evbuomwan, the ability to administer this treatment puts the department, the UFS, and the hospital on the map, alongside other top universities within and outside the country. Says he: “It also creates an avenue for us to gather data for training, research purposes, and publications. We are now able to offer a promising, safe, and highly efficacious therapy for patients with MCRPC in the Free State. Some of these patients will no longer have to travel to other provinces to receive this treatment.”


“We are also well aware that not every patient will respond this way; however, proper patient selection is key in identifying responders – an area that is still being researched. We also do not know how long these patients will have their disease under control after the treatment. Nuclear medicine’s greatest cancer therapy success story is the treatment of well-differentiated thyroid cancer with radioactive iodine.” 

“After treatment, most of these patients remain cancer-free for a very long period of time, if not for life. With continuing research in the field of MCRPC radioligand therapy, we aim to improve the treatment modality, hopefully getting it to the success level of thyroid cancer therapy.”

 

News Archive

First-year students encouraged to attend UFS welcoming function
2007-01-12

Main Campus, Bloemfontein
The University of the Free State (UFS) will host a welcoming function for all new first-year students and their parents on Saturday 13 January 2007 in the Callie Human Centre on the Main Campus in Bloemfontein.
 
The function starts at 11:00 and will be addressed by the Rector and Vice-Chancellor of the UFS, Prof Frederick Fourie. UFS staff will also be available to provide vital information to first-year students on academic matters.
 
Saturday’s welcoming function can assist students and parents by providing vital information on the registration process, which starts on Tuesday 16 January 2007, and the many high quality academic learning programmes on offer in six faculties at the UFS.
 
The UFS has split the registration process into various categories of students and students should adhere to the dates, and times which apply to them as a one-stop service will be available so as to avoid unnecessary delays in the registration process.
 
The registration of first-time entering first-year students who applied before 30 November 2006 to study at the Bloemfontein Campus will take place from Tuesday 16 January 2007 at the Callie Human Centre.
 
Senior undergraduate students (that is, students entering their second or later year of study) may register from 22 January 2007 according to a programme that was sent to all students who were registered at the UFS in 2006.
 
Postgraduate students, first-time entering first-year students and other students, who applied for admission to the Main Campus after 30 November 2006 and were accepted, must register at the Callie Human from 5 February 2007. 
 
Late applications will be accepted until Monday 15 January 2007 at the Information Centre on the Main Campus’ Thakaneng Bridge. 
 
Lectures will commence on 5 February 2007 and the registration process will end on 9 February 2007.
 
Vista Campus:
The Vista Campus in Bloemfontein – which was incorporated into the UFS in January 2004 – no longer accepts applications from first-year students. Such prospective students had to apply to the UFS Main Campus. Students who had been registered on the Vista Campus last year must register at the Vista Campus on the same dates as applicable on the Main Campus.
 
Qwaqwa Campus:
At the Qwaqwa Campus of the UFS all first-time entering first-year students must report on Sunday 14 January 2007 for orientation, after which the registration of these students will take place according to a specific programme as from Wednesday 17 January 2007. The official welcoming functioning for new first-years at the Qwaqwa Campus of the UFS will take place on Saturday 10 February 2007 at 08:00 in the Rolihlahla Mandela Hall on the Qwaqwa Campus.
 
First-year students who have applied to study at the Qwaqwa Campus and their parents should attend this function which fulfils the same role as the one held on the Bloemfontein Main Campus.
 
Detailed information on the dates and times of registration for the various faculties and academic learning programmes is available on the UFS website at www.ufs.ac.za
 
Prospective students may also call the Main Campus in Bloemfontein on 051 4013000 or the Qwaqwa Campus on 058 718-5000 for more information.
 
Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
11 January 2007
 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept